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Abstract
Background: Many cases of frontotemporal dementia (FTD) are familial, often with an autosomal
dominant pattern of inheritance. Some are due to a mutation in the tau- encoding gene, on
chromosome 17, and show an accumulation of abnormal tau in brain tissue (FTDP-17T). Most of
the remaining familial cases do not exhibit tau pathology, but display neuropathology similar to
patients with dementia and motor neuron disease, characterized by the presence of ubiquitin-
immunoreactive (ub-ir), dystrophic neurites and neuronal cytoplasmic inclusions in the neocortex
and hippocampus (FTLD-U). Recently, we described a subset of patients with familial FTD with
autopsy-proven FTLD-U pathology and with the additional finding of ub-ir neuronal intranuclear
inclusions (NII). NII are a characteristic feature of several other neurodegenerative conditions for
which the genetic basis is abnormal expansion of a polyglutamine-encoding trinucleotide repeat
region. The genetic basis of familial FTLD-U is currently not known, however the presence of NII
suggests that a subset of cases may represent a polyglutamine expansion disease.
Methods: We studied DNA and post mortem brain tissue from 5 affected members of 4 different
families with NII and one affected individual with familial FTLD-U without NII. Patient DNA was
screened for CAA/CAG trinucleotide expansion in a set of candidate genes identified using a
genome-wide computational approach. Genes containing CAA/CAG trinucleotide repeats
encoding at least five glutamines were examined (n = 63), including the nine genes currently known
to be associated with human disease. CAA/CAG tract sizes were compared with published normal
values (where available) and with those of healthy controls (n = 94). High-resolution agarose gel
electrophoresis was used to measure allele size (number of CAA/CAG repeats). For any alleles
estimated to be equal to or larger than the maximum measured in the control population, the CAA/
CAG tract length was confirmed by capillary electrophoresis. In addition, immunohistochemistry
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using a monoclonal antibody that recognizes proteins containing expanded polyglutamines (1C2)
was performed on sections of post mortem brain tissue from subjects with NII.
Results: No significant polyglutamine-encoding repeat expansions were identified in the DNA
from any of our FTLD-U patients. NII in the FTLD-U cases showed no 1C2 immunoreactivity.
Conclusion: We find no evidence to suggest that autosomal dominant FTLD-U with NII is a
polyglutamine expansion disease.
Background
Frontotemporal dementia (FTD, OMIM: 600274) is a
neurodegenerative disease characterized by abnormalities
in personality, behaviour and language with relative early
preservation of episodic memory [1,2]. The pathology
underlying clinical FTD is heterogeneous [3]. In some
cases, post mortem examination discloses abnormal accu-
mulations of the microtubule associated protein tau in
neurons and/or glial cells. However, several recent studies
have demonstrated that the most common pathology
associated with clinical FTD is the presence of dystrophic
neurites and neuronal cytoplasmic inclusions in the cere-
bral cortex and hippocampus that are immunoreactive for
ubiquitin (ub-ir) but negative for tau, synuclein and inter-
mediate filament proteins (FTLD-U) [4,5].
FTD is often familial, usually with an autosomal domi-
nant pattern of inheritance. Various studies have demon-
strated genetic linkage to loci on chromosomes 3, 9 and
17 [6-11]. The gene on chromosome 3 and one of the
genes on chromosome 9 have recently been identified
(chmp2B and valosin-containing protein, respectively)
[12,13]. Some cases that show linkage to chromosome 17
are found to have mutations in the gene for tau (MAPT)
and all such cases show tau pathology [14,15]. Familial
FTLD-U has been linked to several different loci on chro-
mosome 9 and to chromosome 17q21 [6,7,10,11,16].
Interestingly, the 17q21 locus contains MAPT, and yet
these cases do not have any tau pathology and have not
had any tau mutations identified [6,7,11]. It remains
unclear whether these cases are due to some, as yet, unrec-
ognized abnormality in MAPT or whether there is another
gene on 17q21 that is responsible for familial FTLD-U.
Recently, we reported that a subset of patients with famil-
ial FTLD-U have the additional post mortem finding of
unusual, lentiform, ub-ir neuronal intranuclear inclusions
(NII) [11,17]. At least some of the cases of familial FTLD-
U with NII are ones that have shown linkage to the 17q21
locus [6,7,11]. NII are uncommon in neurodegenerative
disease in general, but are a characteristic pathological fea-
ture of several conditions for which the genetic basis is
abnormal expansion of a polyglutamine-encoding CAG
trinucleotide repeat within the gene (examples include
Huntington's disease (HD) and several types of spinocer-
ebellar ataxia (SCA) [18-20]. The NII observed in these
diseases are composed in part of aggregates of the
expanded-repeat proteins. In this study, we explore the
possibility that autosomal dominant FTLD-U with NII is a
polyglutamine expansion disease.
Methods
Study cohort
Six patients with familial FTD, from five different families,
were included in the study. In all families studied here, the
pattern of inheritance suggested an autosomal dominant
trait with a high degree of penetrance as previously
described [11,17]. There was no evidence of genetic antic-
ipation in any of the families. Five of the study patients
were deceased and each was from a different family. Post-
mortem neuropathological examination confirmed the
presence of ub-ir neuronal cytoplasmic inclusions charac-
teristic of FTLD-U [Figure 1 a,b] and an absence of signif-
icant tau and α-synuclein pathology (not shown). In four
deceased patients (cases 1–4), numerous ub-ir NII were
also observed. NII had a characteristic lentiform shape
and were most numerous in small neurons of the fronto-
temporal neocortex and striatum [Figure 1c] [17]. The
fifth deceased patient had FTLD-U type pathology but no
NII (case 6). One living patient with FTD was also
included in the study; he was the cousin of one of the
deceased study patients with FTLD-U and NII (case 5).
Therefore, the six study patients represented four families
with FTLD-U with NII (cases 1–5) and one family with
FTLD-U without NII (case 6).
Immunohistochemistry
Post mortem brain tissue from the four deceased study
patients with previously confirmed NII was evaluated.
Formalin fixed, paraffin-embedded tissue sections from
frontal cortex and striatum (areas with maximal numbers
of NII), were immunostained using the Ventana ES auto-
mated system (Ventana, Tuscon, AZ) with primary anti-
bodies against ubiquitin (DAKO, anti-ubiquitin; 1:500,
following microwave antigen retrieval) and proteins with
expanded polyglutamine domains (Chemicon, 1C2;
1:100 following formic acid pre-treatment). Tissue sec-
tions from two patients with known polyglutamine
expansion diseases (one HD and one SCA1) were
included as positive controls.BMC Neurology 2006, 6:32 http://www.biomedcentral.com/1471-2377/6/32
Page 3 of 7
(page number not for citation purposes)
Genetic analysis of polyglutamine-encoding genes
Using a computational approach, we have previously
identified 63 genes in the human genome that contain
tracts of CAG/CAA trinucleotide repeats which encode at
least five consecutive glutamines (Butland et al., in sub-
mission). FTLD-U patient DNA was screened for expan-
sions in these trinucleotide repeat tracts (n = 64),
including the nine tracts whose expansion is currently
known to cause neurodegenerative disorders in humans.
One gene (PCQAP) contains two distinct polyglutamine-
encoding tracts that were screened separately, hence the
disparity in tract number versus gene number.
Gene-specific PCR primers were used to amplify the
repeat-containing loci from the patient DNA, and the
amplicons were subjected to high-resolution gel electro-
phoresis to measure allele size. Metaphor agarose gels
(3% w/v, Mandel Scientific) were run overnight at low
voltage in re-circulated buffer. Under such conditions, it is
possible to resolve small allelic differences [see Additional
file 1]. Gel data were digitised and interpreted with
IMAGE® software, and product sizing was estimated to be
accurate within 6 base pairs. The length of CAG/CAA
tracts was inferred from the overall allele length based on
calibration data we obtained by directly sequencing sev-
eral alleles from each locus. In no case did we observe
allele length differences that arose from sequence changes
outside of the repeat tract. Thus, all allele size changes cor-
respond to differences in the repeat tract alone. From the
present data we cannot, however, determine where in the
repeat tract, such as in the longest contiguous CAG tract,
the expansion is occurring.
The data presented herein refer to the longest uninter-
rupted tract of CAG and CAA trinucleotides in the given
gene. These values were compared to published data (for
known disease loci) and to data obtained from a control
group (n = 94) of unaffected individuals (Butland et al., in
submission). Based on the above resolution limit, all alle-
les estimated to be 6 or more b.p. longer than the longest
control allele were subjected to confirmatory capillary
electrophoresis on an ABI 3700 DNA Analyzer (Applied
Biosystems) and subsequent analysis using GeneMapper
software (Applied Biosystems).
This research was carried out in compliance with the Hel-
sinki Declaration, and ethical approval was provided by
the Clinical Research Ethics Board of the University of
British Columbia (certificate C03-0449).
Results
Neuropathologic analysis of FTLD-U brain tissue
Ubiquitin-positive neurites and neuronal cytoplasmic
inclusions were identified in the superficial cerebral neo-
cortex of the FTLD-U patients (Figure 1a), and similar
Neuropathologic analysis of brain tissue from FTLD-Upa- tients Figure 1
Neuropathologic analysis of brain tissue from FTLD-
Upatients. Ubiquitin immunohistochemistry in cases of 
familial FTLD-U demonstrates staining of (a) neurites and 
neuronal cytoplasmic inclusions in the superficial cerebral 
neocortex, (b) neuronal cytoplasmic inclusions in hippocam-
pal dentate granule cells, and (c) neuronal intranuclear inclu-
sions in the cerebral neocortex (arrows). Scale bar; (a) and 
(b) 40 µm, (c) 25 µm, insert 6 µm.BMC Neurology 2006, 6:32 http://www.biomedcentral.com/1471-2377/6/32
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Table 1: Genetic analysis of FTLD-U DNA samples reveals no significant CAG/CAA repeat expansions in candidate polyglutamine-
encoding genes.
Gene Name (associated polyQ dis-
ease, CAA/CAG tract length of small-
est disease-cuasing allele) a
Control Samples (n = 94) 
estimated CAA/CAG 
tract length
FTD Patients estimated CAA/CAG tract length
case 1b case 2b case 3b case 4b case 5b case 6c
A AR (SBMA, 38) 1 0 – 3 7 2 21 92 0 2 1 ,  2 3 1 92 4
ATN1 (DRPLA, 48) 10–39 18, 23 18, 20 20, 23 19 15, 19 15
ATXN1 (SCA1, 39) 6–39 15, 20 15, 20 16 15, 20 15, 20 14, 21
ATXN2 (SCA2, 37) 2 5 – 4 1 2 22 22 22 22 22 2
ATXN3 (SCA3/MJD, 51) 14–42 15 9 9 9 17 na
ATXN7 (SCA7, 36) 4–35 10 11 10 10 10 10
CACNA1A (SCA6, 20) 4–18 12, 21d 13, 16 15 14 14 13
HD (HD, 36) 10–35 14, 15 12, 17 17, 21 15, 17 12, 14 12
TBP (SCA17, 49) 38–61 39, 44 38, 41 38, 43 36, 39 38, 47 38, 42
B ARID3B 11–13 12 12 12, 16 12, 16 13, 16 13
ASCL1 5–24 13, 17 13 13, 17 13, 18 13, 18 12
BMP2K 22–31 26 26 26 26 26 26
C14orf4 19–24 22, 25 22, 25 23 23 24 23
CXorf6 11–12 12 12 12 11 11 12
DCP1B 10–12 12 na 12 11, 12 11, 12 11, 12
KCNN3 10–43 18 17, 18 na 19, 21 18, 21 18, 20
M E D 1 2 2 6 2 72 62 62 62 62 6
MEF2A 9–16 12, 15 11 12 10, 11 11, 14 11
M I N K 1 5 – 6 666667
M L L 2 6 – 9 999999
NCOA3 25–34 26, 29 28 26, 28 29 28, 29 28
N C O A 6 2 3 – 2 6 2 52 5n a2 42 52 5
NCOR2 13–22 17, 19 17 17 16, 17 13, 17 17, 18
NFAT5 18–21 19 18 18 18 na na
NM 014856 13–17 16 17 14, 16 17 16 14, 16
NUMBL 26 18, 20 18 20 18, 20 18, 20 20
P C Q A P a 1 0 – 1 8 1 11 11 11 01 01 1
P C Q A P b 1 1 – 2 2 1 71 61 61 51 61 6
PHLDA1 15–19 15 15 16 15 15 15
P O L G 1 3 – 1 6 1 31 41 3 1 6 ,  1 7 1 31 3
POU3F2 20–21 15 21, 22 21 21 21 21
POU6F2 7–11 10 10 10 10 10 10
P R D M 1 0 7 – 8 888888
P R K C B P 1 7 – 1 1 887888
RAI1 8–20 14 14 14 14 14 10, 14
RUNX2 26–53 22 21 22 23 23 21
SATB1 12–21 15 15 15 15 15 15
SMARCA2 18–25 22 22 22 22 22 22
S O C S 7 7 – 2 2 8 ,  1 2 88888
TFEB 9–15 12 9 9 9 10 10
TNRC4 14–17 15 15 15 15 15 15
T N R C 6 B 7 – 1 0 9 ,  1 0 99988
T N S 8 – 1 1 1 0 ,  1 2 1 091 091 0
ZNF161 8–22 16, 17 14, 20 14 na 14 14
Z N F 3 8 4 1 1 – 2 0 1 51 61 51 52 01 5
C A R I D 1 B 1 6 – 2 3 1 81 81 91 91 81 8
BAIAP1 16–21 20, 24 19, 25 18, 19 19 20 17, 19
B R D 4 8 – 9 888888
C9orf43 8–9 9 9, 12 88 9 ,   12 8
C H E R P 1 2 1 21 21 21 21 21 2
C I Z 1 6 666666
CREBBP 18 18 18 18 18 18 18
EP400 28–31 30 30, 34 30 30 31 30, 34BMC Neurology 2006, 6:32 http://www.biomedcentral.com/1471-2377/6/32
Page 5 of 7
(page number not for citation purposes)
neuronal cytoplasmic inclusions were found in hippoc-
ampal dentate granule cells (Figure 1b). Ub-ir NII were
found in the cerebral neocortex (arrows, Figure 1c). NII in
the control cases with known polyglutamine disease (HD
and SCA1) were immunoreactive for both ubiquitin and
1C2. In contrast, NII in FTLD-U patients were ub-ir, but
were 1C2 negative (data not shown).
Genetic analysis of FTLD-U DNA samples for CAG/CAA 
repeat expansions in polyglutamine-encoding genes
FTLD-U patient DNA was screened for expansions in the
CAA/CAG trinucleotide repeat tracts of our candidate
genes (Table 1), and the repeat sizes from the study sub-
jects were compared with published normal values and
with those of healthy controls (n = 94) (Butland et al., in
submission). Sixteen small putative expanded alleles were
detected, while the vast majority of alleles from our FTD
patients fell within the range of normal alleles from our
unaffected controls. At least one allele was identified in
each patient that fell just outside the range observed in
our controls samples, and these alleles arose from eight
genes (CACNA1A, ARID3B, BAIAP1, C9orf43, EP400,
FOXP2, MAML2, PAXIP1L). The largest putative expan-
sion identified consisted of a 15 b.p. (~ 5 CAG/CAA)
increase over the largest control allele (case 2, MAML2).
The exact CAG repeat size of all the putative expanded
alleles was confirmed by capillary electrophoresis sizing
and/or direct DNA sequencing, and none of these specific
alleles was found to be expanded in all of the affected
FTDL-U individuals.
Discussion
We have adapted an inexpensive, high-resolution agarose
gel electrophoresis method for the precise sizing of tar-
geted polyglutamine-encoding repeat tracts in the human
genome. Using this method, the normal distribution of
CAG repeat lengths for known disease loci compared
favourably with previously published data and matched
the results obtained by direct sequencing of specific alle-
les, thus confirming the reliability of our method. No sig-
nificant CAA/CAG repeat expansions were detected at the
nine known disease loci in any of the FTLD-U patients.
The initial analysis of the data suggested a putative minor
expansion in the CACNA1A gene (case 1) by gel electro-
phoresis that was subsequently refuted by capillary elec-
trophoresis. This method was subsequently applied to 55
candidate loci that we identified as part of our computa-
tional screen for polyglutamine-encoding tracts in the
human genome (Butland et al., in submission). We iden-
tified 15 alleles from seven genes in our FTLD-U patients
that were 6 or more b.p. longer than the longest control
allele (Table 1, allele sizes in bold text). None of these
small expansions consistently correlated with affected
FTLD-U status in multiple individuals. An allele of
MAML2 harboured the largest putative expansion (15
b.p., case 2). However, according to the annotation of the
reference genome, the trinucleotide repeat tract passes
through a proposed intron. Thus, it is unclear if in fact this
allele would encode an expanded polyglutamine tract in
the protein.
FOXP2 34–40 41 na 41 41 42 42
K I A A 1 8 1 7 2 6 – 2 7 2 72 82 82 82 72 7
K I A A 2 0 1 8 1 1 – 1 6 1 31 41 41 4 1 2 ,  1 7 1 2
MAML2 27–31 29 32, 36 28 28 28, 31 28
MAML3b 18 19 19 19 19 19 19
M N 1 2 6 – 3 0 2 82 82 82 82 8 2 8 ,  2 9
PAXIP1L 7 999888
P H C 1 1 3 – 1 5 1 51 51 51 51 51 5
S T 6 G A L N A C 5 1 2 – 1 4 1 21 21 21 21 21 2
THAP11 18–30 24 24 24, 33 24 24, 26 24, 28
T N R C 6 A 4 – 8 4 ,  8 5 ,  88 85 ,  88
a Genes identified in a computational analysis of polyglutamine repeat-containing genes in the human genome. A) Genes known to cause disease via 
polyglutamine expansion. B) Patient and control samples were both assessed by high resolution agarose gel electrophoresis. C) Control samples 
were analyzed by capillary electrophoresis (Butland et al., in submission) and patient samples analyzed by high resolution agarose gel 
electrophoresis.
b FTDL-U patients with NII.
c FTDL-U patient without NII.
d Alleles 6 or more b.p. longer than the largest contol allele (putative expanded alleles) appear in bold type.
Samples of FTLD-U patient DNA with NII (Cases 1–5) and without NII (Case 6) were screened for expansions in the CAG/CAA trinucleotide 
repeat tracts of our candidate genes including known disease genes (A). The CAG/CAA repeat lengths from the FTLD-U subjects were compared 
with published normal values and with those of healthy controls (n = 94), assessed by high resolution agarose gel electrophoresis (B), and/or 
capillary electrophoresis (C). For the few alleles estimated to be equal to or slightly larger than the maximum measured in our control samples 
(bold), the CAG/CAA repeat length was confirmed by capillary electrophoresis on an ABI 3700 sequencer using GeneMapper software. Using this 
approach, no clinically significant CAG/CAA repeat expansions were identified in the DNA from any of our FTLD-U patients.
Table 1: Genetic analysis of FTLD-U DNA samples reveals no significant CAG/CAA repeat expansions in candidate polyglutamine-
encoding genes. (Continued)BMC Neurology 2006, 6:32 http://www.biomedcentral.com/1471-2377/6/32
Page 6 of 7
(page number not for citation purposes)
Several factors make it unlikely that the small putative
expansions identified are pathogenic. First, there were no
genes for which the allele sizes in FTD patients with NII
(cases 1–5) were consistently larger than those from the
FTD patient without NII (case 6). Second, pathogenic alle-
les of known human polyglutamine disorders typically
encode more than 35 consecutive glutamines whereas
none of our putative expanded alleles encode this many.
Our histopathological findings also support the conclu-
sion than FTLD-U with NII is not a polyglutamine expan-
sion disorder. All known polyglutamine expansions
disorder include the presence of ub-ir NII which also label
with the monoclonal antibody 1C2 [18-20]. The absence
of any 1C2 reactivity in our FTLD-U patient tissue thus
makes it unlikely that their NII contain proteins with
expanded polyglutamine tracts.
Finally, although only a small number of such families
have been reported to date, there is evidence that NII may
be a specific pathological marker for FTLD-U linked to the
chromosome 17q21 locus [6,7,11]. Our computational
approach did not identify any gene in the defined region
of interest that contains at least five CAG or CAA repeats,
although ubiquitinated intranuclear inclusions are
known to occur in triplet repeat disorders encoding for
amino acids other than glutamine (alanine), and in disor-
ders caused by expansions in untranslated regions. This
region does contain 294 non-CAG trinucleotide repeat
tracts of minimum length 5; 11 of which are found within
the coding sequences of 6 known and 3 hypothetical
genes [21]. Thus, a non-glutamine encoding trinucleotide
repeat expansion could still be the basis of the observed
phenotype.
Conclusion
In summary, we find no evidence to suggest that auto-
somal dominant FTLD-U with NII is a polyglutamine
expansion disease. We did not observe immunoreactivity
for expanded polyglutamines within FTLD-U brain, nor
did we identify any alleles with large polyglutamine-
encoding repeat expansions in our set of candidate genes,
which comprises all of the predicted genes of interest with
at least five polyglutamine-encoding CAA/CAG repeats in
the human genome. Furthermore, none of the slightly
longer alleles from FTLD-U subjects within the candidate
genes identified by our computational approach are
found within the various linkage regions established in
prior studies. Therefore, both our genetic analysis and
immunohistochemical data, suggest that the formation of
NII in FTLD-U is due to a mechanism other than accumu-
lation of a protein with a polyglutamine expansion.
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Note added in proof
The conclusions of this manuscript have recently been
verified by two manuscripts: Baker M et al, Mutations in
progranulin cause tau-negative frontotemporal dementia
linked to chromosome 17. Nature. 2006 Aug
24;442(7105):916–9, and Cruts M, et al. Null mutations
in progranulin cause ubiquitin-positive frontotemporal
dementia linked to chromosome 17q21. Nature. 2006
Aug 24;442(7105):920–4. This work identified non-poly-
glutamine encoding mutations in the gene encoding pro-
granulin as the cause of FTLD-U in the subjects we
studied.
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